Observe Medical ASA - Doctoral dissertation further demonstrates clinical benefits of Sippi®

Report this content

Observe Medical ASA, January 15, 2021 – A doctoral (PhD) dissertation at Karolinska Institute, Stockholm, Sweden, demonstrates multiple clinical benefits of the Sippi® automated digital urine meter, and the potential paradigm shift in clinical practice of urine measurement.

The PhD thesis ‘Evaluation of an automatic urinometer including use of silicone oil to decrease biofilm formation due to proteinuria, hemoglobinuria and bacterial growth’ is written by Dr. Martin Slettengren and was dissertated at Dept. of Molecular Medicine and Surgery, Karolinska Institute in Stockholm on January 14, 2021. One of the studies in the thesis was announced in Observe Medical’s release August 17, 2021.

"My thesis shows that the Sippi automatic diuresis measurement system is clearly more appreciated by ward personnel than current manual systems, as it saves them time, is ergonomically superior, and measures diuresis as correct as or better than the manual systems. Accurate monitoring of diuresis is key to detect emerging kidney failure and fluid balance distortions. The ability to monitor trends in diuresis in more detail, combined with the superior usability of the Sippi system, is an important step in improving patient safety in this respect," says Dr. Martin Slettengren.

Dr. Slettengren’s study also shows that silicone oil (Sippcoat®) reduces growth of microbial biofilm formation as well as biofilm coating from albumin and free hemoglobin.

“This improves the performance of the Sippi device substantially and enables it to function for patients with on-going urinary tract infection, albuminuria and hemoglobinuria. Finally, the Sippi detection system (SippSense®) may provide new information for early warning of kidney disease, which could be an indicator for need of clinical preventive actions,” Dr. Slettengren says.

Observe Medical is currently launching Sippi® automated digital urine meter in selected markets in Europe, with the near-term focus on accelerating Sippi® clinical use in the Nordics.

“The pandemic is highlighting key clinical challenges, not the least concerning urine measurement at ICUs and other hospital departments. The recent work by Dr. Martin Slettengren is adding to previous evidence, and further validating Sippi® relevance addressing the key clinical challenges of urine measurement,” says Björn Larsson, CEO of Observe Medical, and continues:

 “We are excited to move into 2021 with full speed and force, strengthened by the findings from the recent work by Dr. Slettengren which further validates the clinical benefits of the Sippi® system.”


For further information, please contact:

Björn Larsson, CEO, mobile: +46 76 620 17 25 E-mail: bjorn.larsson@observemedical.com


About Observe Medical

Observe Medical develops and markets and sells innovative hospital products that contribute to increased patient safety and a more efficient care system. The company’s ambition is to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in the areas of Urine measurement, Anaesthesiology/ICUs and wound care, in combination with targeted M&A. The company’s headquarter is in Oslo, Norway and its operations is based out of Gothenburg, Sweden. Observe Medical has a direct sales organization in the Nordics and a distributor network internationally. Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer to the hospital patient data management systems and hinders bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched with focus on selected markets and hospitals in Nordics and in Europe.